Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients

J Viral Hepat. 2020 Sep;27(9):955-958. doi: 10.1111/jvh.13308. Epub 2020 May 22.

Abstract

Direct-acting antivirals (DAAs) for HCV treatment have improved tolerance and efficacy among adults, but experience in vertical transmission is scarce. In our vertically HIV/HCV co-infected youth cohort of 58 patients, DAA achieved excellent rates of cure among naïve and pretreated individuals. Treating vertically infected seems important as 29.6% displayed advanced fibrosis at treatment initiation.

Keywords: HCV treatment; VIH/VHC co-infection; children and adolescents; direct-acting antivirals; vertical transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antiviral Agents* / therapeutic use
  • Coinfection* / drug therapy
  • HIV Infections* / drug therapy
  • Hepatitis C* / drug therapy
  • Humans

Substances

  • Antiviral Agents